Article
NICE Recommends Gazyvaro for Treatment-Naive CLL Patients
The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.
Patients in England and Wales with chronic lymphocytic leukaemia are a step closer to getting access to Roche’s Gazyvaro (obinutuzumab) on the National Health Service, after cost regulators recommended the drug for routine use.
Gazyvaro is the first ‘type II’ anti-CD20 monoclonal antibody licensed for the treatment of CLL and is designed to attack blood cancers more aggressively than ‘type I’ treatments such as MabThera (rituximab).
Link to the complete article on PharmaTimes: http://bit.ly/1AfH0NA
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
